Reviewing Grace Therapeutics (GRCE) and Its Rivals

Grace Therapeutics (NASDAQ:GRCE) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Grace Therapeutics to related businesses based on the strength of its institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Insider & Institutional Ownership

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.5% of Grace Therapeutics shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Grace Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	0	0	1	0	3.00
Grace Therapeutics Competitors	8408	22247	50400	1349	2.54

Grace Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 500.00%. As a group, “Pharmaceutical preparations” companies have a potential upside of 252.08%. Given Grace Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than its peers.

Risk and Volatility

Grace Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Grace Therapeutics’ peers have a beta of 3.86, meaning that their average stock price is 286% more volatile than the S&P 500.

Earnings & Valuation

This table compares Grace Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grace Therapeutics	N/A	-$12.85 million	-1.72
Grace Therapeutics Competitors	$9.89 billion	$136.37 million	-5.51

Grace Therapeutics’ peers have higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Grace Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-20.10%	-17.10%
Grace Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Summary

Grace Therapeutics beats its peers on 7 of the 13 factors compared.

About Grace Therapeutics

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.